Ferring Pharmaceuticals, the pioneering Swiss pharmaceutical group and world leader in industrial synthesis of peptides, today officially opens its new production site and administrative Headquarters in Saint-Prex in the canton of Vaud. The company has invested more than CHF million in the project and will have created more than jobs by Accompanied by Mrs. Frederik Paulsen, the Chairman of the Board of Ferring, more than guests will today visit the , m2 site in its magnificent Saint-Prex setting.
Pettigrew also emphasized the excellent contacts with the various political and economic authorities of Vaud and the support they provided in bringing the project to successful completion. The 23,m2 building houses all manufacturing stages from production to packaging and distribution, as well as a 3,m2 administrative section. Ferring has invested more than CHF million in the project.
The company employs people today and will be increasing this number to more than by Daylight pervades the metre high building, including the production area, thanks to the use of glass on the façades and in the inside corridors. For the new building, each Ferring subsidiary donated a work of art depicting its respective country, culture or history.
These numerous eye-catching pieces emphasize the spacious proportions of the atrium. At Saint-Prex, we are in a better position to respond to growing demand for our products. Ferring is a Swiss-based, research-driven, specialty biopharmaceutical group active in over 40 countries.
The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, infertility and urology. This page is not intended for patients or for members of the general public.
